Clinical Trial: Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases

U.S., May 30 -- ClinicalTrials.gov registry received information related to the study (NCT07613411) titled 'Safety and Efficacy of KSVCBD Injection in Autoimmune Diseases' on May 22.

Brief Summary: KSVCBD injection is an in vivo Chimeric Antigen Receptor T-Cell (CAR-T cell) therapy product. This single-arm, open-label, early exploratory clinical study is designed to evaluate the safety and preliminary efficacy of KSVCBD injection in patients with Autoimmune Diseases.

Study Start Date: June 01

Study Type: INTERVENTIONAL

Condition: Autoimmune Diseases

Intervention: DRUG: KSVCBD injection

KSVCBD injection is an in vivo CAR-T therapy targeting CD19/BCMA and is administered by IV infusion.

Recruitment Status: NOT_YET_RECRUITING

Sponsor...